Abstract
Our living environment is a melting pot for more than 4.5 million natural and synthetic chemicals, which an individual may come in contact with at any given time: only 10,100 of them have been described in the Merck Index (11th Ed., 1989). It is now thought that a lifetime’s continuous exposure to trace amounts of endogenously formed and/or environmental toxins (such as industrial chemicals, pesticides, food additives, or abused and therapeutic drugs), may provoke neuronal degenerative events such as those occurring in Parkinson’s and other diseases (Barbeau et al., 1987; Schoenberg et al., 1987a; Tanner, 1989; Koller et al., 1990; Calne, 1991; see Dawson et al., 1995). A process, in other words, similar to the continuous gnawing of small wood-worms which can lead to the destruction of even huge pieces of furniture. Epidemiologic and experimental evidence supports this hypothesis. In industrialized countries, during the last 100 years, there has been an unequivocal lengthening of the life expectancy of individuals, accompanied by a dramatic increase in the rate of neurodegenerative Parkinson’s and Alzheimer’s diseases (Lilienfeld et al., 1990; Rajput, 1992). Meanwhile, the threshold age for the onset of Parkinsonism has fallen (Schoenberg, 1987b; Tanner, 1989). On the other hand, in the developing countries less likely to suffer from environmental pollution, the incidence of Parkinson’s disease is much lower (Schoenberg, 1987b), and Alzheimer’s dementia is actually absent in Nigeria (Osuntokun et al., 1991). It is true that an increase in the average age, and thus the greater number of vulnerable individuals, may play an important role in increasing the incidence of neurodegenerative diseases in developed countries. While the existence of a clear correlation has been demonstrated between neuropathies and exposure to selected environmental toxicants (Barbeau et al., 1987; Rajput et al., 1987; Schoenberg, 1987a: Tanner, 1989; Calne, 1991; Semchuk et al., 1992; Dawson et al., 1995), there is only controversial evidence that genetic factors may help neurotoxicity (Golbe, 1990; Rajput, 1992; Vieregge, 1994).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Adams, J.D., Klaidman, L.K. & Leung, A.C. MPP+ and MPDP+ induced oxygen radical formation with mitochondria) enzymes. Free Radical Biol.Med. 15, 181–186 (1993).
Ali, S.F., David, S.N., Newport, G.D., Cadet, J.L. & Slikker, W. MPTP-induced oxidative stress and neurotoxicity are age-dependent: evidence from measures of reactive oxygen species and striatal dopamine levels. Synapse 18, 27–34 (1994).
Amenta, F., Zaccheo, D. & Collier, W.L. Neurotransmitters, neuroreceptors and aging. Mech.Ageing.Devl. 61, 249–273 (1991).
Ando, S. & Tanaka, Y. Synaptic membrane aging in the central nervous system. Gerontology 36 (SI), 10–14 (1990).
Bagchi, S.P. Trace dosages of the neurotoxins MPTP and MPP+ may affect brain dopamine in vivo. Life Sci. 51, 389–396 (1992).
Bannon, M.I., Poosch, M.S., Xia, Y., Goebbel, DJ., Cassin, B. & Kapatos. G. Dopamine transporter mRNA content in human substantia nigra decreases precipituously with age. Proc.Natl.Acad.Sci. USA 89, 7095–7099 (1992).
Barbeau, A., Roy, M., Bernier, G. et al. Ecogenetics of Parkinson’s disease: prevalence and environmental aspects in rural areas. C’an.J.Neurol.Sci. 14, 36–48 (1987).
Borowsky, B. & Hoffman, B.J. Neurotransmitter transporters: molecular biology, function, and regulation. Int.RecNeurohiol. 38, 139–199 (1995).
Breese, G.R. & Taylor, T.D. Effects of 6-hydroxydopamine on brain norepinephrine and dopamine: evidence of selective degeneration of catecholamine neurons. J.Pharmacol.Exp.Ther. 174, 413–420 (1970).
Caine, D.B. Neurotoxins and degeneration in the central nervous system. Neurotoxicology 12, 335–340 (1991).
Carlsson, A. & Winblad, D.B. Influence of age and time interval between death and autopsy on dopamine and 3-methoxytyramine levels in human basal ganglia. J.Neural Transm. 38, 271–276 (1976).
Collins, M. A possible neurochemical mechanism for brain and nerve damage associated with chronic alcoholism. Trends Pharmacol.Sci. 3, 373–375 (1982).
Darchen, F., Scherman, D. & Henry, J.-P. Reserpine binding to chromaffin granules suggests the existence of two conformations of the monoamine transporter. Biochemistry 28, 1692–1697 (1989).
Dawson, R. Jr., Beal, M.F., Bondy, S.C., Di Monte, D.A. & Isom, G.E. Excitotoxins, aging, and environmental neurotoxins: implications for understanding human neurodegenerative diseases. Toxicol.Appl.Pharntacol. 134, 1–17 (1995).
Del Zompo, M., Piccardi, M.P., Ruiu, S., Quartu, M., Gessa, G.L. & Vaccari, A. Selective MPP+ uptake into synaptic dopamine vesicles: possible involvement in MPTP toxicity. BI:J.Pharmacol. 109, 411–414 (1993).
Desai, V.G., Feuers, R.J., Hart, R.W. & Ali, S.F. MPP+-induced neurotoxicity in mouse is age-dependent: evidence by the selective inhibition of complexes of electron transport. Brain Res. 715, 1–8 (1996).
Dobrev, D., Bergsträsser, E., Fischer, H.-D. & Andreas, K. Restriction and functional changes of dopamine release in rat striatum from young adult and old rats. Mech.Ageing Devl. 80, 107–119 (1995).
Edwards, R.H. Neural degeneration and the transport of neurotransmitters. Ann.Neurol. 34, 638–643 (1993).
Emerich, D.F., McDermott, P., Krueger, P. et al. Locomotion of aged rats: relationship to neurochemical but not morphologic changes in nigrostriatal dopaminergic neurons. Brain Res.Bull. 32, 477–486 (1993).
Erickson, J.D., Schäfer, M.K.-H., Bonner, T.I., Eiden, L.E. & Weihe, E. Distinct pharmacological properties and distribution in nervous and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc.Natl.Acad.Sci.USA 93, 5166–5171 (1996).
Finnegan, K.T., Irwin, I., Delanney, L.E. & Langston, J.W. Age-dependent effects of the 2’-methyl analog of Imethyl-4-phenyl-1,2,3,6-tetrahydropyridine: prevention by inhibitors of monoamine oxidase-B. J.Pharmocol.Exp.Ther. 273, 716–720 (1995).
Forster, M.J., Dubey, A., Dawson, K.M., Stutts, W.A., Lai, H. & Sohal, R.S. Age-related losses of cognitive function and motor skills in mice are associated with oxidative protein damage in the brain. Pmc.Natl.Acad.Sci.USA 93, 4765–4769 (1996).
Golbe, L.I. The genetics of Parkinson’s disease: a reconsideration. Neurology 40 (S3) 7–14 (1990).
Gupta, M., Gupta, B.K., Thomas, R., Bruemmer, V., Sladek, J.R. & Felten, D.L. Aged mice arc more sensitive to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine than young adults. Neurosci.Lett. 70, 326–331 (1986).
Henry, J.-P. & Seherman, D. Radioligands of the vesicular monoamine transporter and their use as markers of monoamine storage vesicles. Biochem.Pharmacol. 38, 2395–2404 (1989).
Huang, R.-L., Wang, C.-T., Tai, M.-Y., Tsai, Y.-F. & Peng, M.-Y. Effects of age on dopamine release in the nucleus aecumbens and amphetamine-induced locomotor activity in rats. Neurosci.Lett. 200, 61–64 (1995).
Hyde, C.E. & Bennett, B.A. Similar properties of fetal and adult amine transporters in the rat brain. Brain Res. 646, 118–123 (1994).
Irwin, I., Ricaurte, G.A., Delanney, L.E. & Langston, J.W. The sensitivity of nigro-striatal dopamine neurons to MPP` does not increase with age. Neurosci.Lett. 87, 51–56 (1988).
Irwin, I., Finnegan, K.T., Delanney, L.E., Di Monte, D. & Langston, J.W. The relationships between aging, monoamine oxidase, striatal dopamine and the effects of MPTP in C57BL/6 mice: a critical reassessment. Brain Res. 572, 224–231 (1992).
Jarvis, M.F. & Wagner, G.C. Age-dependent effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neuropharmacology 24, 581–583 (1985).
Johannessen, J.N. A model of chronic neurotoxicity: long-term retention of the neurotoxin 1-methyl-4-phenylpyridinium (MPP`) within catecholaminergic neurons. Neurotoxicologr 12, 285–302 (1991).
Johnson, R.G. Jr. Accumulation of biological amines into chromaffin granules: a model for hormone and neurotransmitter transport. Physiol.Rev. 68, 232–307 (1988).
Jonec, V. & Finch, C.E. Senescence and noradrenaline uptake by subcellular fractions of the C57BL/6J male mouse brain. Brain Res. 91, 197–203 (1975).
Kabuto, H., Yokoi, I., Mori, A., Murakami, M. & Sawada, S. Neurochemical changes related to ageing in the senescence-accelerated mouse brain and the effect of chronic administration of nimodipine. Mech.Ageing Devi. 80, 1–9 (1995).
Koller, W., Vetere-Overfield, B., Gray, C. et al. Environmental risk factors in Parkinson’s disease. Neurology 40, 1218–1221 (1990).
Langston, J.W., Irwin, I. & Delanney, L.E. The biotransformation of MPTP and disposition of MPP’: the effects of aging. Life Sci. 40, 749–754 (1987).
Lilienfeld, D., Chan, E., Ehland, J. et al. Two decades of increasing mortality from Parkinson’s disease among the US elderly. Arch.Neurol. 47, 731–734 (1990).
Liu, Y., Peter, D., Roghani, A., Schuldiner, S., Privé, G.G., Eisenberg, D., Brecha, N. & Edwards, R.H. A cDNA that suppresses MPP+ toxicity encodes a vesicular monoamine transporter. Cell 70, 539–551 (1992).
Liu, Z., Stafstrom, C.E., Sarkisian, M., Tandon, P., Yang, Y., Hori, A. & Holmes, G.L. Age-dependent effects of glutamate toxicity in the hippocampus. Devl.Brain Res. 97, 178–184 (1996).
Makino, Y., Ohta, S., Tachikawa, O. & Hirobe, M. Presence of tetrahydroisoquinoline and 1-methyl-tetrahydroisoquinoline in foods: compounds related to Parkinson’s disease. Life Sci. 43, 373–378 (1988).
Milgram, N.W., Racine, R.J., Nellis, P., Mendonca, A. & Ivy, G.O. Maintenance on L-deprenyl prolongs life in aged male rats. Life Sci. 47, 415–420 (1990).
Myers, R.D. Isoquinolines, beta-carbolines and alcohol drinking: involvement of opioid and dopaminergic mechanisms. Experientia 45, 436–443 (1989).
Nakano, M. & Mizuno, T. Age-related changes in the metabolism of neurotransmitters in rat striatum: a microdialysis study. Mech.Ageing Devl. 86, 95–104 (1996).
Naudon, L., Raisman-Vozari, R., Edwards, R.H., Leroux-Nicolet, L, Peter, D., Liu, Y. & Costentin, J. Reserpine affects differentially the density of the vesicular monoamine transporter and dihydrotetrabenazine binding sites. Eur.J.Neurosci. 8, 842–846 (1996).
Osterburg, H.H., Donahue, H.G., Severson, J.A. & Finch, C.E. Catecholamine levels and turnover during aging in brain regions of male C57BL/6J mice. Brain Res. 224, 337–352 (1981).
Osuntokun, B.O., Ogunniyi, A.O., Lekwauka, G.U. et al. Epidemiology of age-related dementias in the third-world and etiologic clues of Alzheimer’s disease. Tropical Geogr.Med. 43, 345–351 (1991).
Pradhan, S.N. Central neurotransmitters and aging. Life Sci. 26, 1643–1656 (1980).
Rajput, A.H. Epidemiology of Parkinson’s disease. Can.J.Neurol.Sci. 11S, 154–161 (1984).
Rajput, A.H., Uitti, R.G., Stern, W. et al. Geography, drinking water chemistry, pesticides and herbicides and the etiology of Parkinson’s disease. Can.J.Neurol.Sci. 14, 414–418 (1987).
Rajput, A.H. Frequency and cause of Parkinson’s disease. Can.J.Neurol.Sci. 19, 103–107 (1992).
Ramsay, R.R., Krueger, M.J., Youngster, S.K. & Singer, T.P. Evidence that the inhibition sites of the neurotoxic amine 1-methyl-4-phenylpyridinium (MPP*) and the respiratory chain inhibitor piericidin A are the same. Biochem.J., 273, 481–484 (1991).
Reinhard, J.F. Jr., Carmichael, S.W. & Daniels, A.J. Mechanisms of toxicity and cellular resistance to I-methy1–4phenyl-1,2,3,6-tetrahydropyridine and I-methyl-4-phenyl-pyridinium in adrenomedullary chromaffin cell cultures.J.Neurochem. 55, 311–320 (1990).
Ricaurte, G.A., Irwin, I., Forno, L.S., Delanney, L.E., Langston, E.B. & Langston, J.W. Aging and I-methyl-4phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra. Brain Res. 403, 43–51 (1987a).
Ricaurte, G.A., Delanney, L.E., Irwin, I. & Langston, J.W. Older dopaminergic neurons do not recover from the effects of MPTP. Neuropharmacology 26, 97–99 (1987b).
Riekkinen, P. Jr., Riekkinen, M., Valjakka, A., Riekkinen, P. & Sirviö, J. DSP-4, a noradrenergic neurotoxin, produces more severe biochemical and functional deficits in aged than young rats. Brain Res. 570, 293–299 (1992).
Riekkinen, M., Aroviita, L., Kivipelto, M., Taskila, K. & Riekkinen, P. Jr. Depletion of serotonin, dopamine and noradrenaline in aged rats decreases the therapeutic effect of nicotine, but not of tetrahydroaminoacridine. Eur.J.Phafmacol. 308, 243–250 (1996).
Ross, S.B. Long-term effects of N-2-chloroethyl-N-ethyl-2-bromobenzylamine hydrochloride on noradrenergic neurones in the rat brain and heart. BrJ.Pharmacol. 58, 521–527 (1976).
Rothstein, J.D., Jin, L., Dykes-Hoberg, M. & Kuncl, R.W. Chronic inhibition of glutamate uptake provides a model of slow neurotoxicity. Proc.Natl.Acad.Sci.GSA 90, 6591–6595 (1993).
Saransaari, P. & Oja, S.S. Age-related changes in the uptake and release of glutamate and aspartate in the mouse brain. Mech.Ageing Devl. 81, 61–71 (1995).
Scherman, D., Raisman, R., Ploska, A. & Agid, Y. [3H]Dihydrotetrabenazine, a new in vitro monoaminergic probe for human brain. J.Neurochem. 50. 1131–1136 (1988)
Scherman, D., Desnos, C., Darchen, F., Pollak, P., Javoy-Agid, F. & Agid, Y. Striatal dopamine deficiency in Parkinson’s disease: role of aging. Ann.Neurol. 26, 551–557 (1989).
Schoenberg, B.S. Environmental risk factors for Parkinson’s disease: the epidemiologic evidence. Can.J.Neurol.Sci. 14, 407–413 (1987a).
Schoenberg, B.S. Descriptive epidemiology of Parkinson’s disease: disease distribution and hypothesis formulation. Adv. Neurol. 45, 277–283 (1987b).
Semchuk, K.M., Love, E.J. & Lee, R.G. Parkinson’s disease and exposure to agricultural work and pesticide chemicals. Neurology 42, 1328–1335 (1992).
Simantov, R. Neurotransporters: regulation, involvement in neurotoxicity, and the usefulness of antisense nucleic acids. Biochem.Pharmacol. 50, 435–442 (1995).
Sirviö, J., Riekkinen, P. Jr., Valjakka, A., Jolkkonen, J. & Riekkinen, P.J. The effects of noradrenergic neurotoxin, DSP-4, on the performance of young and aged rats in spatial navigation task. Brain Res. 563, 297–302 (1991).
Slivka, A. & Cohen, G. Hydroxyl radical attack on dopamine. J.Biol.Chem. 260, 15466–15472 (1985).
Tanner, C.M. The role of environmental toxins in the etiology of Parkinson’s disease. Trends Neurosci. 12, 49–54 (1989).
Tipton, K.F. & Singer, T.P. Advmces in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J.Nelrochem. 61, 1191–1206 (1993).
Vaccari, A. High-affinity binding of [31–1]-tyramine in the central nervous system. BrJ.Pharmacol. 89, 15–25 (1986).
Vaccari, A. The tyramine binding site in the central nervous system: An overview. Neurochern.Res. 18. 861–868 (1993).
Vaccari, A. & Gessa, G.L. [31–1]Tyramine binding: a comparison with neuronal [3H]dopamine uptake and [31-]mazindol binding processes. Neurochem.Res. 14, 949–955 (1989).
Vaccari, A., Del Zompo, M., Melis, F., Gessa, G.L. & Rossetti, Z.L. Interaction of l-methyl-4-phenylpyridinium ion and tyramine with a site putatively involved in the striatal vesicular release of dopamine. BrJ.Pharmacol. 104, 573–574 (1991).
Vaccari, A., Saba, P.L., Gessa, G.L. & Del Zompo, M. Differential interaction of I-methyl-4-phenylpyridinium ion with the putatively vesicular binding site of [3H]tyramine in dopaminergic and nondopaminergic brain regions. J.Neurochem. 60, 758–760 (1993).
Vaccari, A. & Saba, P.L. The tyramine-labelled vesicular transporter for dopamine: a putative target of pesticides and neurotoxins. Eur.J.Pharmacol.(ETPS) 202, 309–314 (1995).
Vaccari, A., Saba, P.L., Ruiu, S., Collu, M. & Devoto, P. Disulfiram and diethyldithiocar-bamate intoxication affects the storage and release of striatal dopamine. Toxicol.Appl.Pharmacol. 139, 102–108 (1996).
Vieregge, P. Genetic factors in the etiology of idiopathic Parkinson’s disease. J.Neural Transco. (P-D Sect.) 8, 1–37 (1994).
Vingerhoets, F.J., Snow, B.J., Tetrud, J.W., Langston, J.W., Schulzer, M. & Caine, D.B. Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann.Neurol. 36, 765–770 (1994).
Walsh, S.L. & Wagner, G.C. Age-dependent effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): correlation with monoamine oxidase B. Synapse 3, 308–314 (1989).
Wustmann, C., Schmidt, J., Ihle, W., Gross, J. & Fischer, H.-D. Dopamine release from striatum slices of rats at different age: influence of hypoxia. Biomed.Biochem.Acta 42, 265–273 (1983).
Zelnik, N., Angel, I., Paul, S.M. & Kleinman, J.E. Decreased density of human striatal dopamine uptake sites with age. Eur.J.Pharmacol. 126, 175–176 (1986).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer Science+Business Media New York
About this chapter
Cite this chapter
Vaccari, A., Saba, P., Mocci, I., Ruiu, S. (1997). Is Increased Neurotoxicity a Burden of the Ageing Brain?. In: Filogamo, G., Vernadakis, A., Gremo, F., Privat, A.M., Timiras, P.S. (eds) Brain Plasticity. Advances in Experimental Medicine and Biology, vol 429. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9551-6_16
Download citation
DOI: https://doi.org/10.1007/978-1-4757-9551-6_16
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-9553-0
Online ISBN: 978-1-4757-9551-6
eBook Packages: Springer Book Archive